InSightec's ExAblate(R) 2000 System Recognized as One of Advanced Imaging's '2005 Imaging Solutions of the Year'

    HAIFA, Israel, Feb. 16 /PRNewswire/ -- InSightec today announced that its
 ExAblate(R) 2000 system was highlighted as one of Advanced Imaging's '2005
 Imaging Solutions of the Year' in its recent issue. Recently approved by the
 U.S. Food and Drug Administration for the non-invasive surgery of symptomatic
 uterine fibroids, the system is currently in use around the world for the
 treatment of uterine fibroids and clinical trials are underway for both benign
 and cancerous tumors such as breast fibroadenoma, breast cancer, brain tumors,
 bone tumors and liver tumors.
     This is the third time the Company has been recognized for its MRgFUS
 technology. Other awards include the 2004 Grand Prize by the European Union's
 Information Society Technology and the Bronze Medal in Wall Street Journal
 2004 Technology Innovation Award competition.
     "ExAblate 2000 offers a patient-friendly uterine-sparing outpatient
 treatment for women with symptomatic uterine fibroids," Dr. Jacob Vortman,
 president and CEO, InSightec said. "Advanced Imaging's recognition reiterates
 the importance of this breakthrough technology as a non-invasive surgical
 procedure that will allow patients to return quickly to normal life. ExAblate
 is the first FDA approved system to use focused ultrasound for therapy and MRI
 imaging for real time control of the treatment."
     ExAblate(R) 2000 is the first system to combine Magnetic Resonance Imaging
 (MRI) with high-intensity focused ultrasound to thermally ablate (destroy)
 tissue without any incisions. ExAblate 2000 was approved by the FDA in October
 2004 after it was granted an expedited review because of the significant
 advantages afforded by this technology over existing treatments for uterine
 fibroids.
     ExAblate 2000 is compatible only with General Electric Healthcare's SIGNA
 Magnetic Resonance systems. Currently, nine major medical centers in the
 United States are equipped with the ExAblate 2000 System:
 
     -- Brigham and Women's Hospital in Boston, MA.
     -- The Johns Hopkins Hospital in Baltimore, MD
     -- Mayo Clinic in Rochester, MN
     -- University MRI in Boca Raton, FL
     -- Tower Beverly Radiology - Radnet in Beverly Hills, CA
     -- Virtua Health in Voorhees, NJ
     -- The Lahey Clinic in Burlington, MA
     -- Cornell Weill Medical Center, New York, NY
     -- UCSD Medical Center in San Diego, California
 
     Systems are also installed in London, Berlin, Tel Aviv, and in several
 locations in Japan.
     Physicians, patients or hospital administrators interested in learning
 more about ExAblate 2000 for the treatment of symptomatic uterine fibroids may
 call 1-866-EXABLATE. Patient information is also available at
 http://www.uterine-fibroids.org.
 
     About InSightec
 
     InSightec Image Guided Treatment Ltd. is a privately held company owned by
 Elbit Medical Imaging (EMI), General Electric, private investors and
 employees. It was founded in 1999 to develop the breakthrough MR guided
 Focused Ultrasound technology and transform it into the next generation
 operating room. Headquartered near Haifa, Israel, the company has over 100
 employees and has invested more than $60 million in research, development, and
 clinical investigations. Its U.S. headquarters are located in Dallas, Texas.
 For more information, please go to: http://www.insightec.com
 
      For more information contact:
      InSightec
      http://www.insightec.com
      Tel: +972-4-813-1329
      Email: info@insightec.com
 
      For media inquiries, contact:
      Laura Yoshida
      Phone: +1-212-867-1762
      Email: lyoshida@lazarpartners.com
 
 
 

SOURCE  InSightec Ltd.